Modi's Jan Aushadhi Success: Delivering Affordable Healthcare For The Common Man
The promise of affordable, quality medicine for everyone is within reach, but only if we dare to confront the obstacles and build on the hard-won successes
India stands at a fascinating, if somewhat contradictory, crossroads in healthcare. We proudly wear the mantle of the “world’s pharmacy", supplying affordable generic medicines across continents, while back home, a fierce battle rages over the very soul of affordable medicine access for our own people.
The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), or Jan Aushadhi scheme, is the epicentre of this conflict—a vital initiative aiming to slash the crippling burden of healthcare costs, yet facing stiff headwinds from powerful quarters. Its rapid expansion offers cause for celebration, but a closer look, particularly through a state-level lens, reveals crucial lessons we must heed if this quiet revolution is to transform India’s health landscape.
related stories
A Numbers Game We’re Winning (Mostly)
Let’s not mince words: the sheer pace of Jan Aushadhi’s growth in recent years is remarkable. From a sluggish start with a mere 80 Kendras by 2015, the network has exploded, crossing the 15,000 mark by early 2024-25, smashing government targets ahead of schedule. Think about it—at one point, a new government-backed generic drug store was opening roughly every two hours. And it wasn’t just bureaucratic box-ticking where stores were being opened just for the sake of it; it translated into tangible relief for millions. Union health minister JP Nadda recently highlighted a staggering Rs 28,000 crore saved by patients purchasing medicines through these Kendras, thanks to discounts ranging from 50 to an incredible 80 per cent compared to branded equivalents.
This expansion signifies a direct assault on the high out-of-pocket expenditure (OOPE) on medicines that tragically pushes an estimated 7 per cent of our population below the poverty line each year. While Jan Aushadhi sales, hovering around Rs 1,500 crore annually, are still a fraction of India’s massive Rs 1.5 lakh crore pharmaceutical market, their impact punches far above its weight. Studies suggest every rupee spent in a Jan Aushadhi Kendra saves households around six rupees—a lifeline for families struggling to afford essential, often life-saving, treatments. This momentum, contributing to a significant drop in overall health OOPE over the last decade, is something to champion as it represents a concrete step towards making healthcare a right, not a privilege dictated by the depth of one’s pockets.
The Geographic Lottery
However, the national aggregate, impressive as it is, masks significant disparities on the ground. The distribution of Jan Aushadhi Kendras reveals a ‘geographic lottery’ – a stark variation in access depending on where you live. While the milestone of having at least one Kendra in every district across India has been achieved, a significant improvement from just a few years ago, the population coverage varies dramatically.
Kerala boasts impressive coverage with roughly one Kendra per 17,000 people, while states like Jharkhand lag significantly, with coverage closer to one Kendra per 270,000 citizens. This uneven spread means the scheme’s benefits aren’t reaching everyone equally, potentially leaving those in poorer, more remote states further behind.
Encouragingly, efforts are bearing fruit. The focus on expanding into the 112 ‘Aspirational Districts’—areas identified for accelerated development—seems to be working. A significant proportion of these historically underserved districts now host multiple Kendras, suggesting that government incentives to establish outlets in challenging areas are having some effect. Yet, counterintuitively, a higher percentage of more developed districts still only have a single Kendra compared to aspirational districts.
So, simply opening stores isn’t enough; we need more nuanced, state-specific strategies that account for local healthcare ecosystems, including parallel state-run generic medicine schemes, and address the unique barriers in different regions. Ensuring equitable access requires more than just dotting the map; it demands a deep understanding of local needs and challenges.
The Quality Conundrum
No discussion of Jan Aushadhi is complete without tackling the issue of quality. It’s the persistent shadow hanging over the scheme, fuelled by genuine concerns and, arguably, strategic FUD (Fear, Uncertainty, and Doubt) campaigns. Tragic incidents, like the child deaths in Gambia and Uzbekistan linked to Indian-made cough syrups (DownToEarth), rightly raise alarm bells about regulatory oversight. India is awash with substandard drugs, a damning indictment of our current system. This reality provides fertile ground for opponents of Jan Aushadhi to sow doubts about the unbranded generics sold in these Kendras.
The opposition is vocal and influential. Ironically, the Indian Pharmaceutical Alliance (IPA), representing the generics giants who once fought multinationals using arguments about patient access, now resists the expansion of unbranded generics that threaten their lucrative branded-generic market. They, along with parts of the medical fraternity like the Indian Medical Association (IMA)—which fiercely opposed mandatory generic prescribing—often frame their resistance around quality concerns.
Yet, organisations like the All-India Drug Action Network (AIDAN) argue that commercial interests are the primary driver, fearing that widespread acceptance of cheap, unbranded generics will bust the myth that only renowned brands are of good quality. The PMBJP scheme mandates procurement only from WHO-GMP-certified manufacturers and requires batch testing in NABL-accredited labs. While implementation fidelity is always a question, dismissing the entire scheme based on the broader regulatory failures, which affect branded drugs too seems disingenuous. The battle here is as much about market share and profit margins as it is about patient safety.
Charting the Path Forward
Jan Aushadhi’s journey so far offers critical lessons for strengthening affordable healthcare across India. Ignoring them would be a strategic blunder.
First, regulatory overhaul is non-negotiable. The persistent doubts about quality, exploited by vested interests, stem from a fundamentally weak drug regulatory system. We desperately need to strengthen the Central Drugs Standard Control Organisation (CDSCO) and state FDAs, vastly increase the number of qualified drug inspectors, and enforce a zero-tolerance policy towards substandard and spurious medicines. Public trust, the bedrock of any successful public health initiative, can only be built on the assurance of consistent quality, rigorously monitored and enforced. Without this, the “generic revolution" will remain stalled.
Second, perception management is paramount. The deep-seated belief, often encouraged by market forces, that higher price equals higher quality, needs to be systematically dismantled. Sustained, high-profile public awareness campaigns are essential to build confidence in generic medicines. Allowing the substitution of branded prescriptions with generic equivalents at Jan Aushadhi Kendras, a move fiercely resisted by the industry, is a crucial step in demonstrating therapeutic equivalence directly to patients. We must proactively shape the narrative, celebrating the quality controls in place and highlighting the immense savings potential.
Third, expansion must be strategic and equitable. While celebrating the overall growth, the focus must intensify on plugging the gaps in underserved areas—the lagging states, the remote districts, and the tribal belts. The success in Aspirational Districts shows that targeted incentives can work, but they need continuous refinement and monitoring to ensure they genuinely improve access for the most vulnerable. This requires moving beyond national targets to granular, district-level planning.
Finally, sustained political will is critical. The accelerated growth of Jan Aushadhi under recent governments demonstrates what focused political commitment can achieve. This momentum must be maintained. It requires continued investment, not just in opening stores, but in strengthening the entire supply chain, ensuring medicine availability (addressing past stockout issues), and robustly overseeing quality.
Conclusion: Delivering on the Promise
The Jan Aushadhi scheme is more than just a network of pharmacies; it’s a potent symbol of India’s potential to deliver affordable healthcare to its citizens. Its expansion represents significant progress, saving crores and easing the burden on millions. But its journey is far from over. The challenges – geographical disparities, entrenched opposition, and the critical need for regulatory strengthening – are formidable. Addressing these requires honesty, strategic clarity, and unwavering commitment.
By learning the lessons from the ground up, tackling the quality concerns head-on, and ensuring equitable access, India can ensure that its role as the “pharmacy of the world" translates into tangible health benefits for all Indians. The promise of affordable, quality medicine for everyone is within reach, but only if we dare to confront the obstacles and build on the hard-won successes.
- Location :
- First Published: